Can Fite Biopharma Ltd

詳細情報 Can Fite Biopharma Ltd 企業名

Can Fite Biofarma Ltd is an Israel-based clinical-stage biopharmaceutical company engaged in developing orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The Company co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. It's technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention.

企業情報

企業コードCANF

会社名Can Fite Biopharma Ltd

上場日Sep 22, 2005

最高経営責任者「CEO」Dr. Pnina Fishman, Ph.D.

従業員数5

証券種類Ordinary Share

決算期末Sep 22

本社所在地10 Bareket Street, Kiryat Matalon

都市PETAH TIKVA

証券取引所Tel Aviv Stock Exchange

国Israel

郵便番号49170

電話番号97239241114

ウェブサイトhttps://www.canfite.com/

企業コードCANF

上場日Sep 22, 2005

最高経営責任者「CEO」Dr. Pnina Fishman, Ph.D.

役員一覧

会社名

会社名/ポジション

ポジション

株式保有

変動額

Mr. Yaacov Goldman

Independent Director

--

Mr. Guy Regev

Independent Director

--

Dr. Abraham Sartani, M.D.

Independent Director

--

Dr. Ilan Cohen

Chairman of the Board

--

Dr. Pnina Fishman, Ph.D.

Chief Executive Officer, Director

--

Mr. Motti Farbstein

Chief Financial Officer, Chief Operating Officer

--

Dr. Sari Fishman, Ph.D.

Vice President - Business Development

--

Mr. Yoseph Borenstein

Director

--

会社名

会社名/ポジション

ポジション

株式保有

変動額

Mr. Yaacov Goldman

Independent Director

--

Mr. Guy Regev

Independent Director

--

Dr. Abraham Sartani, M.D.

Independent Director

--

Dr. Ilan Cohen

Chairman of the Board

--

Dr. Pnina Fishman, Ph.D.

Chief Executive Officer, Director

--

Mr. Motti Farbstein

Chief Financial Officer, Chief Operating Officer

--

収益内訳

データなし

データなし

事業別

地域別

データなし

株主

更新時刻: Sat, Sep 6

株主統計

種類

株主統計

比率

Sabby Management, LLC

4.94%

Rhumbline Advisers Ltd. Partnership

0.37%

Abalone Asset Management Ltd.

0.15%

BNP Paribas Securities Corp. North America

0.11%

Two Sigma Investments, LP

0.10%

他の

94.33%

株主統計

比率

Sabby Management, LLC

4.94%

Rhumbline Advisers Ltd. Partnership

0.37%

Abalone Asset Management Ltd.

0.15%

BNP Paribas Securities Corp. North America

0.11%

Two Sigma Investments, LP

0.10%

他の

94.33%

種類

株主統計

比率

Investment Advisor/Hedge Fund

4.94%

Investment Advisor

0.65%

Research Firm

0.19%

Hedge Fund

0.10%

他の

94.11%

機関投資家保有株

更新時刻: Tue, Jul 1

報告期間

機関投資家数

保有株式数

比率

変動額

2025Q2

29

155.14K

1.06%

-711.63K

2025Q1

30

155.14K

1.17%

-710.63K

2024Q4

28

154.43K

1.51%

-671.86K

2024Q3

26

794.33K

11.46%

+115.72K

2024Q2

26

667.93K

11.77%

+152.94K

2024Q1

24

517.69K

9.97%

+253.94K

2023Q4

29

283.94K

5.78%

+189.77K

2023Q3

28

67.77K

1.66%

-429.92K

2023Q2

28

54.74K

1.34%

-433.22K

2023Q1

31

368.56K

9.03%

+211.26K

詳細を見る

株主動向

会社名

保有株式数

比率

変動額

変動率

日付

Rhumbline Advisers Ltd. Partnership

38.27K

0.29%

+11.39K

+42.37%

Mar 31, 2025

Abalone Asset Management Ltd.

23.81K

0.18%

-16.19K

-40.48%

Jun 30, 2024

BNP Paribas Securities Corp. North America

22.59K

0.17%

-2.60K

-10.32%

Mar 31, 2025

CAPTRUST Financial Advisors

10.63K

0.08%

+10.63K

--

Mar 31, 2025

Morgan Stanley & Co. LLC

23.21K

0.17%

-9.30K

-28.60%

Mar 31, 2025

MainStreet Advisors

3.00K

0.02%

--

Mar 31, 2025

Wells Fargo Advisors

2.70K

0.02%

+200.00

+8.00%

Mar 31, 2025

詳細を見る

0.646USD

Can Fite Biopharma Ltd

0.646

概要

企業名

金融

分析